Stereotactic radiotherapy for patients with oligometastatic cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the effectiveness of stereotactic radiation therapy in patients with oligometastatic cancer, which is characterized by 1 to 5 metastatic tumors in various locations. Patients who have undergone a line of chemotherapy will be randomized to receive either stereotactic radiation therapy or standard palliative care. The methodology includes advanced imaging techniques for precise targeting of tumors and minimizing radiation exposure to healthy tissues. The goal is to improve treatment outcomes compared to conventional palliative approaches.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Histologically confirmed malignant formation (ICD 10-11 codes С18, С19, С20, С34, С50, С61, С64).
2. 0-2 points on the WHO/ECOG scale of assessment of the general condition of the patient.
3. The absence of disease progression after the current line of chemotherapeutic treatment.
4. The number of oligometastases is not more than 3 in one organ, in the presence of a multi-organ lesion.
5. The total number of distant metastases is no more than 5.
6. Life expectancy of more than 6 months for brain metastases (GPA-score)
7. The possibility of SBRT for all distant metastases, in accordance with the criteria specified in the study design.
8. Making decisions on the inclusion of a patient in the study protocol based on the results of an interdisciplinary consultation consisting of an oncologist, a chemotherapist and a radiotherapist.
9. Signed informed consent

Exclusion Criteria:

1. 3-4 points on the WHO/ECOG scale of assessment of the general condition of the patient
2. The complete response of all foci to the chemotherapy.
3. Distant metastases only in the brain, without damage to bones and other organs.
4. Brain metastasis of more than 3 cm in one dimension, requiring surgical treatment.
5. Distant metastasis in the brain stem and spinal cord.
6. The size of at least one distant metastasis is more than 5 cm.
7. Previously performed radiation therapy on one of the metastatic foci.
8. Metastatic lesion of the pleura, membranes of the brain or peritoneum.
9. The impossibility of CTT for all distant metastases, in accordance with the criteria specified in the study design.
10. Invasion into great vessels (aorta, carotid arteries, pulmonary arteries, etc.), organs of the digestive tract (esophagus, stomach, intestines), skin.
11. Compression of the spinal cord by distant metastasis according to instrumental studies.

Where it's running

• A. Tsyb Medical Radiological Research Center
  Obninsk, Kaluga Oblast, Russia Recruiting

Study contacts

• Principal investigator: Konstantin Gordon — A. Tsyb Medical Radiological Research Center
• Study coordinator: Konstantin Gordon, PhD
• Email: gordon@mrrc.obninsk.ru
• Phone: +79105184148

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Immediate simulation-free SBRT for people with up to five metastatic tumors

  This tests whether giving stereotactic body radiation therapy (SBRT) right away without a separate CT simulation helps people with up to five metastatic cancer spots get treatment faster.

  Recruiting Phase 1 Case Comprehensive Cancer Center · Cleveland, Ohio · NCT07079098

• Stereotactic ablative radiotherapy versus single‑fraction palliative radiotherapy for oligoprogressive metastatic cancer

  This trial will test whether stereotactic ablative radiotherapy (SABR) works better than single‑fraction palliative radiotherapy (8 Gy) for people with 1–5 oligoprogressive metastatic lesions to delay the need for next‑line systemic therapy and improve quality of life.

  Recruiting British Columbia Cancer Agency · Surrey, British Columbia · NCT06918951

• Chemoimmunotherapy followed by surgery for limited spread esophageal and gastric cancer

  This study is testing if a combination of chemotherapy, immunotherapy, and surgery can help people with a limited spread of esophageal or gastric cancer live longer and have fewer recurrences.

  Recruiting University Health Network, Toronto · Toronto, Ontario · NCT06668454

• Combining radiotherapy with systemic therapy for oligometastatic ureter cancer

  This study tests if adding radiotherapy to standard treatment can help people with a limited number of metastatic ureter cancer spots feel better and live longer.

  Recruiting at 2 sites Peking University First Hospital · Beijing and 1 other locations · NCT06652022

• Single‑fraction versus multiple‑fraction SBRT for treating limited metastases (SPRINT)

  This trial will test whether a single high‑dose SBRT treatment works as safely and effectively as multiple smaller SBRT treatments for people with limited metastases from breast, prostate, lung, or colorectal cancer.

  Recruiting at 2 sites European Organisation for Research and Treatment of Cancer - EORTC · Aalst and 14 other locations · NCT06462963

• Combining radiation therapy with ATRA for treating oligo-metastatic solid cancers

  This study is testing whether combining a specific type of radiation therapy with a medication called ATRA can help people with certain solid cancers that have spread to a few places in the body.

  Recruiting Phase 1/2 Gustave Roussy, Cancer Campus, Grand Paris · Lyon and 1 other locations · NCT06439888

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.